Zobrazeno 1 - 10
of 1 283
pro vyhledávání: ''
Publikováno v:
Alimentary Pharmacology & Therapeutics. 55:380-388
Background Ustekinumab and vedolizumab are commonly used after anti-tumour necrosis factor (TNF) failure in patients with Crohn's disease (CD). No randomised controlled trial has compared these drugs. Aims To compare the effectiveness of ustekinumab
Publikováno v:
Alimentary Pharmacology & Therapeutics. 55:455-463
Background Since azathioprine is associated with lymphoproliferative disorders in Epstein-Barr virus (EBV)-naive patients with inflammatory bowel disease, guidelines advise avoidance. No recommendations exist for autoimmune liver disease (AILD). Aims
Autor:
Ailsa Hart, James L. Alexander, Lucy C. Hicks, Horace R T Williams, Julian Marchesi, Kate Gallagher, Jia V. Li, Nick Powell, Benjamin H. Mullish, Shiva T. Radhakrishnan
Publikováno v:
Alimentary Pharmacology & Therapeutics. 55:26-48
Background The gut microbiota has been implicated in the pathogenesis of inflammatory bowel disease (IBD), with Faecalibacterium prausnitizii associated with protection, and certain genera (including Shigella and Escherichia) associated with adverse
Publikováno v:
Alimentary Pharmacology & Therapeutics. 54:1370-1388
BACKGROUND Drug-induced gastrointestinal injury has been increasingly reported, but its exact incidence is not known. The small and large intestines represent the most affected sites of injury, accounting for 20%-40% of all gastrointestinal side effe
Autor:
Chinmay Trivedi, Tyler Pernes, Dhruvan Patel, Himanshu Kavani, Yu-Xiao Yang, Dawei Xie, Nabeel Khan
Publikováno v:
Alimentary Pharmacology & Therapeutics. 55:64-72
BACKGROUND There are limited data on the incidence of pneumonia and pneumonia-related hospitalisation in the IBD population, and on any association of IBD medications with such outcomes. AIMS To evaluate the impact of IBD medications on the risk of p
Autor:
Matthias Laudes, Nicholas A Kennedy, Jasmijn A M Sleutjes, Klaudia Farkas, Jeanine E. Roeters van Lennep, C. Janneke van der Woude, Annemarie C. de Vries, Eric Boersma, Marieke Pierik, Luis Menchén, Tamás Molnár
Publikováno v:
Alimentary Pharmacology & Therapeutics. 54(8):999-1012
Background: Increase in lipid levels associated with the treatment of inflammatory bowel disease (IBD) has previously been reported. However, it is unknown if this effect is similar for all IBD drug classes.Aim: To precisely assess the effect of diff
Autor:
Esteban Gonzalez Ballerga, Andrea Paes de Lima, Pilar Carballo, Jorge Daruich, Fernando Barreyro, J.A. Sorda, Alejandra Avagnina
Publikováno v:
Alimentary Pharmacology & Therapeutics. 54:1202-1212
Ursodeoxycholic acid (UDCA) is the first-line therapy for primary biliary cholangitis (PBC). However, nearly 40% of patients have an incomplete response to UDCA. The addition of bezafibrate has shown biochemical benefit in this group of patients.To e
Autor:
Bindia Jharap, Nofel Mahmmod, Bas Oldenburg, Michiel T. van der Kaaij, J Schultheiss, Boris P. van Hellemondt, J Louwers, Petra G van Boeckel, Herma H. Fidder, Remi Mahmoud
Publikováno v:
Alimentary Pharmacology & Therapeutics. 54:1298-1308
BACKGROUND Inflammatory bowel disease (IBD) is often managed with anti-tumour necrosis factor-α therapy (anti-TNFα), but treatment efficacy is compromised by high annual rates of loss of response (13%-21% per patient-year). AIMS To assess whether t
Autor:
Kento Takenaka, Ryuichi Okamoto, Mamoru Watanabe, Masakazu Nagahori, Kohei Suzuki, Hiromichi Shimizu, Eiko Saito, Kazuo Ohtsuka, Shuji Hibiya, Ami Kawamoto, Maiko Motobayashi, Toshimitsu Fujii
Publikováno v:
Alimentary Pharmacology & Therapeutics. 54:1052-1060
Background Several studies have reported a positive correlation between serum drug concentrations and endoscopic remission in patients with Crohn's disease. Aim To examine the association between the concentrations of cytokine blockers (infliximab, a
Autor:
Mathurin Fumery, Jérôme Filippi, Vered Abitbol, Amélie Biron, David Laharie, Melanie Serrero, Romain Altwegg, Yoram Bouhnik, Laurent Peyrin‐Biroulet, Cyrielle Gilletta, Xavier Roblin, Guillaume Pineton de Chambrun, Lucine Vuitton, Anne Bourrier, Stephane Nancey, Jean‐Marc Gornet, Stephane Nahon, Guillaume Bouguen, Stephanie Viennot, Maria Nachury, Aurelien Amiot, Franck Brazier, Clara Yzet, Xavier Hebuterne, Guillaume Cadiot, Hedia Brixi, Pauline Rivière, Florian Poullenot, Xavier Treton, Carmen Stefanescu, Camille Zallot, Laurent Beaugerie, Philippe Seksik, Harry Sokol, Julien Kirchgesner, Gilles Boschetti, Bernard Flourié, Claire Gay, Pauline Danion, Chloe Venturin, Matthieu Allez, Clotilde Baudry, Benjamin Pariente, Pauline Wils, Charlotte Gagnière, Jenny Tannoury
Publikováno v:
Alimentary Pharmacology and Therapeuthics
Alimentary Pharmacology and Therapeuthics, 2021, 54 (7), pp.944-951. ⟨10.1111/apt.16544⟩
Alimentary Pharmacology and Therapeuthics, 2021, 54 (7), pp.944-951. ⟨10.1111/apt.16544⟩
International audience; Background Phase III trials have demonstrated the efficacy and safety of ustekinumab in ulcerative colitis (UC), but few real-life long-term data are currently available. Aims To assess the real-world effectiveness and safety